J&J's Prostate Cancer Drug Zytiga Approved for Earlier Use in EU

On Friday, Johnson & Johnson's (NYSE: JNJ  ) Zytiga received an expanded approval from the European Commission. The drug was previously approved for patients with metastatic castration-resistant prostate cancer who have failed a chemotherapy regimen that contains Sanofi's (NYSE: SNY  ) Taxotere. The new approval expands the use of Zytiga into patients who have failed androgen deprivation therapy, but who aren't appropriate for chemotherapy yet.

The European Commission's decision is a rubber stamp on the European Medicines Agency's Committee for Medical Products for Human Use's decision in November to recommend the expanded marketing authorization.

The expanded approval is based on a clinical trial of more than 1,000 patients comparing Zytiga, plus prednisone/prednisolone, to placebo, plus prednisone/prednisolone. Patients in the Zytiga arm had a statistically-significant improvement in radiographic progression-free survival, a measure of how quickly a tumor begins to grow. Treatment with Zytiga also produced longer overall survival, although the trial was stopped early, so the difference didn't reach statistical significance.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2192441, ~/Articles/ArticleHandler.aspx, 9/22/2014 8:40:33 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement